<DOC>
	<DOCNO>NCT00841321</DOCNO>
	<brief_summary>The purpose study see treatment Ginkgo improve cognitive function people multiple sclerosis cognitive problem .</brief_summary>
	<brief_title>Trial Ginkgo Treatment Cognitive Problems Multiple Sclerosis</brief_title>
	<detailed_description>Objectives : Primary objective : Determine difference subject treat Ginkgo biloba ( GB ) subject treat placebo 12 week performance battery neuropsychological test frequently impair Multiple Sclerosis ( MS ) : Stroop test , Paced Auditory Serial Addition Test ( PASAT ) , California Verbal Learning Test ( CVLT-II ) , Controlled Oral Word Association Test ( COWAT ) . Secondary objective : Determine difference two group treatment follow outcome : 1 ) incidence treatment related side effect , 2 ) cognitive performance report subject Perceived Deficits Questionnaire , 3 ) cognitive performance report subject 's family member caregiver measure Multiple Sclerosis Neuropsychological Screening Questionnaire 4 ) community integration measure Community Integration Questionnaire . Research plan : This randomize double blind placebo control trial GB 120 mg twice day 12 week . Methods : One hundred fifty-eight subject ( 79 per group ) randomly assign placebo GB . Subjects evaluate baseline exit cognitive test battery self report measure detail . For primary outcome , multivariate analysis covariance ( MANCOVA ) use analyze change cognitive test simultaneously . This analysis follow analysis covariance ( ANCOVA ) cognitive test battery . The sample size select power 0.80 alpha level 0.05 overall MANCOVA ANCOVA 's Bonferroni 's correction . The self report measure analyze use ANCOVA baseline response covariates . Safety evaluation include complete blood count metabolic panel well physical exam baseline exit . The physical exam include Expanded Disability Scale ( EDSS ) . Telephone follow-ups do monthly treatment one month exit study review study procedure assess side effect . Adverse reaction classify use category grade Cancer Therapy Evaluation Program ( CTEP ) Common Toxicity Criteria ( CTC ) Version 3.0 report Institutional Review Board ( IRB ) follow institution guideline . A Data Safety Management Board ( DSMB ) oversee study .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>A diagnosis multiple sclerosis McDonald 's criterion Age 18 65 year , inclusive A score minus one standard deviation mean one follow test : PASAT , COWAT , CVLTII , Stroop EDSS 0 7.5 , inclusive No Ginkgo biloba precede 30 day Native English speaker Current substance abuse disorder , psychosis , significant depression ( score Beck Depression Inventory II ( BDI II ) great 28 Any significant uncontrolled medical problem include diabetes require insulin Relapse multiple sclerosis within 30 day screen Abnormalities coagulation current use anticoagulant antiplatelet agent Elective surgery plan study period follow four week Epilepsy history seizure Use nifedipine , nicardipine , Saint John 's Wort , papaverine , mono amine oxidase inhibitor Pregnancy woman use reliable form contraception Corrected binocular visual acuity bad 20/50 one error binocular color vision test Ishihara Color Plates sustain nystagmus diplopia primary gaze Inability complete neuropsychological test battery screen visit History alcohol abuse illicit drug use prior six month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Ginkgo biloba</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Cognition</keyword>
	<keyword>Neuropsychological Tests</keyword>
	<keyword>Neurobehavioral Manifestations</keyword>
	<keyword>Quality life</keyword>
	<keyword>Randomized Controlled Trials</keyword>
	<keyword>Placebos</keyword>
	<keyword>Double-Blind Method</keyword>
</DOC>